PGEN — Precigen, Inc.
Precigen, Inc. is an American company dedicated to the discovery and development of cutting-edge gene and cellular therapies. The company also offers disease-modifying treatments, genetically engineered swine for regenerative medicine, and advanced reproductive and embryo transfer technologies. Its extensive portfolio of proprietary platforms includes UltraVector, which leverages advanced DNA construction and computational modeling to engineer complex gene expression programs; mbIL15, a gene designed to enhance immune cell function; the non-viral Sleeping Beauty transposon/transposase system for genetic modification; and AttSite recombinases, tools for precise DNA recombination. Furthermore, Precigen utilizes its AdenoVerse platform, a library of engineered adenovectors for gene delivery and immunotherapy applications, alongside L. lactis, a food-grade bacterium. The company also provides RheoSwitch, an inducible gene switch system offering quantitative, dose-proportionate control over target protein expression's timing and amount; kill switches, designed to selectively eliminate cell therapies within the body; tissue-specific promoters for targeted gene expression; the UltraCAR-T platform for cancer treatment; and the ActoBiotics platform, which employs genetically modified bacteria to deliver proteins and peptides directly to mucosal sites. Precigen maintains strategic collaboration and license agreements with Alaunos Therapeutics, Inc., Ares Trading S.A., Oragenics, Inc., Castle Creek Biosciences, Inc., and Intrexon Energy Partners I and II, LLC. Established in 1998, Precigen, Inc., previously known as Intrexon Corporation, adopted its current name in January 2020 and is headquartered in Germantown, Maryland.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ Global Select
- Employees: 143
- Website: https://www.precigen.com
Latest SEC filings for PGEN
- 10-Q — 2026-08-04
- 8-K — 2026-08-04
- 8-K — 2026-06-24
- 10-Q — 2026-05-13
- 8-K — 2026-05-13
- 10-K — 2026-03-25
- 8-K — 2026-03-25
- 10-Q — 2025-11-13
- 8-K — 2025-11-13
- 8-K — 2025-09-17
Latest PGEN news
- — PGEN Stock Up More Than 50% in 3 Months: Here's What You Should Know (zacks.com)
- — Beat the Market Like Zacks: Thermo Fisher, Cricut, Shopify in Focus (Zacks Investment Research)
- — 4 Low-Beta Healthcare Stocks to Buy Amid Fears of Another Rate Hike (Zacks Investment Research)
- — Precigen (PGEN) Soars 6.3%: Is Further Upside Left in the Stock? (Zacks Investment Research)
- — Precigen (PGEN) Soars 6.3%: Is Further Upside Left in the Stock? (zacks.com)
- — uniQure Plunges on Additional Data From Huntington's Disease Study (Zacks Investment Research)
- — PGEN vs. IRWD: Which Biotech Stock Offers Better Growth Potential? (Zacks Investment Research)
- — IOVA Stock Hits 52-Week High on Raised Revenue Outlook for 2026 (Zacks Investment Research)
- — Here's Why You Should Add URGN Stock to Your Portfolio Now (Zacks Investment Research)
- — PGEN vs. IRWD: Which Biotech Stock Offers Better Growth Potential? (zacks.com)
Educational tool only — not investment advice.